Aviron Message Board - Msg: 3528371

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron

AVIR 3.375

+1.7%

3:18 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: j bayer who wrote (207)	2/25/1998 2:22:00 PM
From: s jones	Read Replies (1) of 645

Recent highlights for Biota have included: Commencement of North American trials of its influenza diagnostic. Biota expects its innovative diagnostic to be submitted for regulatory clearance in the United States in the second quarter of 1998. Phase III clinical trials in the Northern Hemisphere of RelenzaTM, the first effective treatment for all strains of influenza. RelenzaTM is being developed by Biota in partnership with Glaxo Wellcome and filing for regulatory clearance worldwide is expected in the second half of 1998. The decision to proceed with the next stage in the development of a potent new series of anti-cancer compounds licensed from LaTrobe University in April 1997. The goals for the next 12 months will be to select the most active and promising drug candidate to take forward into clinical development, to strengthen the patent position and to identify a backup to the lead compound.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next